Insights from 2023 ASCO® Annual Meeting

 

Insights from 2023 ASCO® Annual Meeting
P

Enfortumab Vedotin in the Previously Treated Advanced Head & Neck Cancer Cohort of EV-202

By Insights from 2023 ASCO® Annual Meeting FEATURING Paul Swiecicki
By Insights from 2023 ASCO® Annual Meeting FEATURING Paul Swiecicki
233 views
June 29, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

19:38
Exelixis

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Feat. R. Alter, A. Rezazadeh

Featured Video

20:14
Exelixis

Hypothetical Patient Case: RAI-R Metastatic Differentiated Thyroid C…

Feat. R. Alter, R. Shameem
Head and Neck
06:27

Enfortumab Vedotin in the Previously Treated Advanced Head & Neck Ca…

Insights from 2023 ASCO® Annual Meeting

P. Swiecicki

233 views
09:16

ASCO® 2023 Insights: "Phase 3 Double-Blinded Randomized Controlled T…

Insights from 2023 ASCO® Annual Meeting

E. Cathcart-Rake

77 views
13:06

ASCO® 2023 Summary: "Key H&N Cancer Studies Including FRAIL-IMMUNE &…

Insights from 2023 ASCO® Annual Meeting

P. Bossi

938 views
15:11

Immunotherapy Trials for Nasopharyngeal Cancers

Insights from 2023 ASCO® Annual Meeting

N. Saba

402 views